um ski Cancer Research Institute, which h been a defendant in the civil action. The application for the warrant was supported by the affidavit of FDA Compliance Offi- cer, Kenneth P. Ewing. Ewing stated that the application was based on FDA inspec- tions and investigations of Dr. Burzynski and the Institute